|
Novo Nordisk's operating profit increased by 15% in the first quarter of 2010
|
27 April 2010 |
|
Superior efficacy of Victoza® (liraglutide) compared to Januvia® (sitagliptin)
|
23 April 2010 |
|
Novo Nordisk launches international survey into the psychosocial effects of living with haemophilia
|
16 April 2010 |
|
Novo Nordisk Introduces New Industry Resource for Information on Diabetes and Chronic Disease
|
31 March 2010 |
|
Novo Nordisk receives FDA approval for Norditropin® FlexPro® for growth hormone treatment
|
04 March 2010 |
|
Novo Nordisk receives approval for Victoza® in Japan
|
25 January 2010 |
|
Novo Nordisk starts phase 1 trial with long-acting oral GLP-1 analogue
|
14 January 2010 |
|
Novo Nordisk starts phase 1 trial with oral insulin analogue
|
08 December 2009 |
|
Novo Nordisk increased operating profit by 30% in the first nine months of 2009
|
30 October 2009 |
|
The 4-T study of intensified insulin regimens shows excellent three-year glucose control
|
23 October 2009 |
|
Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities
|
29 June 2009 |
|
New study first ever to directly compare once-daily Levemir® with another basal insulin analogue
|
03 June 2009 |
|
Novo Nordisk reaches settlements regarding Oil-for-Food activities
|
11 May 2009 |
|
Novo Nordisk and VLST Corporation announce collaboration agreement
|
29 December 2008 |
|
Children in the world's poorest countries to get free insulin
|
04 December 2008 |
|
Novo Nordisk and Innate Pharma swap product rights
|
07 October 2008 |
|
Data from one-year liraglutide phase 3 study published in The Lancet
|
29 September 2008 |
|
Novo Nordisk acquires intellectual property rights from Neose Technologies
|
18 September 2008 |
|
Novo Nordisk launches a next generation of FlexPen®
|
09 September 2008 |
|
Novo Nordisk joins the Call to Action for gender equality
|
21 August 2008 |